



FOR IMMEDIATE RELEASE:

Contact: Cyntellect
Jim Linton, Ph.D.
Chief Business Officer
USA Phone: 001 858 382 7678
jlinton@cyntellect.com

Cyntellect Awarded \$1.3MM Phase II SBIR Grant to Automate Cloning of Cells Based on Protein Secretion

Novel application of LEAP™ to accelerate cell-based R&D and manufacturing efforts

San Diego, CA – May 9, 2007 – Cyntellect, Inc., a privately-held biotechnology company, today announced it will receive approximately \$1.3MM in funding under a Phase II Small Business Innovative Research (SBIR) grant for continued new application development on its laser-based LEAP™ system. Specifically, the grant will fund further development of applications using LEAP for automated high-speed purification and cloning of cells based upon their specific secretion of native or recombinant proteins. Purification and cloning of cells based on specific protein secretion rate allows researchers to:

- generate high-purity cell samples for improved biomarker and gene expression studies;
- develop optimized cell lines for functional screening assays resulting in better data quality;
- explore complex systems biology and differentiation pathways; and
- improve the efficiency of protein production for various research and therapeutic applications.

“The ability to perform high-speed purification and cloning of cells based on various functional cell properties, such as the secretion rate of specific proteins, opens up exciting new avenues of research activities in areas ranging from biologics discovery to cell line development to cellular diagnostics,” stated Dr. Fred Koller, President and CTO. “This grant award recognizes the substantial progress reported from our Phase I efforts and highlights the significance of this LEAP application for contributing to new and important scientific discoveries.”

About Cyntellect

Cyntellect, Inc. is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company’s web site at www.cyntellect.com.